Pertuzumab
Perjeta (pertuzumab) is an antibody pharmaceutical. Pertuzumab was first approved as Perjeta on 2012-06-08. It is used to treat breast neoplasms in the USA. It has been approved in Europe to treat breast neoplasms. The pharmaceutical is active against receptor tyrosine-protein kinase erbB-2.
| Trade Name | Perjeta |
|---|---|
| Common Name | Pertuzumab |
| Indication | breast neoplasms |
| Drug Class | Monoclonal antibodies: humanized, tumors as target |
